Globeflex Capital L P Purchases Shares of 522,099 Cerus Corporation $CERS

Globeflex Capital L P acquired a new position in Cerus Corporation (NASDAQ:CERS) during the second quarter, HoldingsChannel reports. The institutional investor acquired 522,099 shares of the biotechnology company’s stock, valued at approximately $1,525,000.

Several other hedge funds have also modified their holdings of CERS. Cibc World Markets Corp purchased a new position in shares of Cerus in the fourth quarter valued at $25,000. CIBC Bancorp USA Inc. purchased a new stake in Cerus during the third quarter valued at $31,000. Dynamic Technology Lab Private Ltd purchased a new stake in Cerus during the first quarter valued at $32,000. Y Intercept Hong Kong Ltd bought a new position in Cerus during the first quarter valued at $35,000. Finally, Aquatic Capital Management LLC bought a new position in Cerus during the third quarter valued at $35,000. 78.37% of the stock is owned by hedge funds and other institutional investors.

Cerus Trading Down 4.3%

Shares of NASDAQ CERS opened at $2.69 on Tuesday. Cerus Corporation has a fifty-two week low of $1.17 and a fifty-two week high of $3.47. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.07 and a current ratio of 1.83. The company has a market cap of $542.09 million, a price-to-earnings ratio of -89.67 and a beta of 1.81. The business’s 50 day moving average price is $2.83 and its 200-day moving average price is $2.44.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, July 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 10.19% and a negative net margin of 3.06%.The company had revenue of $63.30 million during the quarter, compared to analysts’ expectations of $62.90 million. On average, sell-side analysts expect that Cerus Corporation will post -0.04 earnings per share for the current year.

Insider Activity

In related news, insider Chrystal Jensen sold 30,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $2.98, for a total value of $89,400.00. Following the transaction, the insider owned 936,657 shares of the company’s stock, valued at $2,791,237.86. This trade represents a 3.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Kevin Dennis Green sold 33,676 shares of Cerus stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $2.94, for a total transaction of $99,007.44. Following the sale, the chief financial officer owned 1,062,188 shares of the company’s stock, valued at $3,122,832.72. The trade was a 3.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 269,404 shares of company stock valued at $787,293. Insiders own 5.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CERS. BTIG Research upgraded shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Friday, May 1st. Wall Street Zen downgraded shares of Cerus from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. Zacks Research upgraded Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $4.00.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.